Search
Atosiban
go.drugbank.com/drugs/DB09059ApprovedInvestigationalIt was first reported in the literature in 1985. Atosiban is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant adult women. … Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor.
Products: Atosiban Accord 6,75 mg/0,9 ml Injektionslösung in einer FertigspritzeAnethole trithione
go.drugbank.com/drugs/DB13853Approvedhepatitis [L2388] and is marketed in certain countries like France, Germany, and China [A32614]. … Anethole trithione (ATT) appears to have a broad range of unique functions, from increasing salivary secretion to help treat xerostomia [A27165, A32618, A32620, A32621], to demonstrating an ability to
Lifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalThe ophthalmic solution was approved in July, 2016 under the trade name Xiidra. … It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast onset of action and well tolerated profile in both local and systemic setting [A18805].
Categories: Compounds used in a research, industrial, or household settingCiltacabtagene autoleucel
go.drugbank.com/drugs/DB16738ApprovedInvestigationala range of symptoms including bone pain, hematologic abnormalities, and end-organ damage. … [A245854] While normally expressed on plasma blasts and plasma cells, BCMA is widely expressed on malignant plasma cells and most multiple myeloma cell lines, making it a choice target in the development
Rimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigationalsafer for use in patients with contraindications to standard therapy. … Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals.
Evinacumab
go.drugbank.com/drugs/DB15354ApprovedInvestigational[A229273] Loss-of-function mutations in _ANGPTL3_ have been noted to result in hypolipidemia and subsequent reductions in cardiovascular risk, whereas increases in function appear to be associated with … Evinacumab is novel in its mechanism of action compared with other lipid-lowering therapies and therefore provides a unique and synergistic therapeutic option in the treatment of HoFH.
Durvalumab
go.drugbank.com/drugs/DB11714ApprovedInvestigationalsmall cell lung cancer (ES-SCLC). … [L12621] In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in
Trametinib
go.drugbank.com/drugs/DB08911ApprovedInvestigational[A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission on June 30, 2014. … [A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma.
Triclabendazole
go.drugbank.com/drugs/DB12245ApprovedInvestigationalTriclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans. … Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use.
Margetuximab
go.drugbank.com/drugs/DB14967ApprovedInvestigational[A225751] The introduction of [trastuzumab] improved patient outcomes in HER2-positive breast cancer, but notably depended substantially on polymorphisms in the FcγRIIIA/CD16A receptor, whereby low affinity … produced in Chinese Hamster Ovary (CHO) culture.